changes in cancer treatment

A new frontier of precision targeting in lethal cancers


EP31670 (= NEO2734)

A first-in-class oral once daily drug

Guided by a very wide range of preclinical studies, this powerful drug was selected among many other drug candidates to potently and specifically inhibit different validated cancer drug targets: BET (BRD4) + p300/CBP + CECR2 + TAF1 + BRPF1 + GCN5. Treatment results in both halted tumor growth as well as halted metastasis formation. This powerful drug fights cancer in multiple ways: (1) by eradicating tumor cells directly (cytotoxic therapy), (2) by unleashing the body’s immune system (immunotherapy), and (3) by inhibiting cancer-inducing male and female hormone actions (hormone therapy). Crucially, there exist mutations in specific cancers that render the tumor cells exquisitely sensitive to EP31670. Clinical trials are ongoing at MD Anderson Cancer Center, Dana-Farber Cancer Institute and University of Washington/Fred Hutchinson Cancer Research Center with other leading cancer centers soon also joining.

Read more
Read more


Primary indications where all are backed by unprecedented preclinical data.

  • Myeloid (blood cancer) malignancies

  • Metastatic castrate resistant prostate cancer (mCRPC)

  • NUT midline carcinoma (NC)

  • Pancreatic cancer (PDAC)

  • Breast cancer (TNBC and ER+)

Read more

IND 158612

IND in January 2022: ” study may proceed”


Below are links to articles regarding EP31670 (=NEO2734) 

(additional publications forthcoming)